Ph.D., Co-Founder and Advisor, Astrocyte Pharmaceuticals | Director, Optical Imaging Core at UT Health San Antonio
A researcher in the School of Medicine at The University of Texas Health Science Center at San Antonio, Professor James Lechleiter, received a U.S. patent (No. 8,618,074) Dec. 31 for his discovery that a class of compounds is protective against traumatic brain injury (TBI). The experimental test tissues pictured were obtained from a 60-year- old human patient who had undergone a temporal lobectomy to relieve epilepsy. Neurons are visible in red, astrocytes (caretaker cells) in green. The specimen on the right was placed in a solution containing 2-methylthio- ADP, one of a class of compounds called purinergic receptor ligands. The specimen on the left was placed in untreated solution. The specimens are shown five days after ischemic trauma that usually results in killing of neurons and astrocytes. 2-methylthio-ADP preserved many neurons and astrocytes in the treated specimen. Dr. Lechleiter is also the Director of the Optical Imaging Core, a key laboratory at UT Health San Antonio which serves as a resource for neuroscientists in the region.
Concussions, stroke and other traumatic brain injuries (TBI) can lead to permanent brain damage. Our entrepreneurial researchers explore new treatments and therapeutics to treat and prevent damage from TBI. Hear from our panel of experts in neuroscience and sports medicine as they share their latest innovations and treatments. UT Health San Antonio panel includes: Jim […]